Anti nkp30

Manufactured by BioLegend

Anti-NKp30 is a monoclonal antibody that binds to the NKp30 receptor on natural killer (NK) cells. NKp30 is a key activating receptor on NK cells that plays a role in their cytotoxic function. The Anti-NKp30 antibody can be used to study the biology and function of NK cells.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

NKp30 (6 citations) Anti-NKp30 (P30-15, (5 citations) Anti-NKp30-APC (4 citations) Anti-NKp30 (clone P30-15, (2 citations) PE-anti-human CD337 (NKp30) (2 citations) Anti-NKp30 PE (2 citations)

4 protocols using anti nkp30

Comprehensive NK Cell Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following fluorescently conjugated antibodies were used for phenotypic analysis of NK cells: anti-LFA-1 (363404); anti-CXCR3 (353720); anti-PD-1 (329906); anti-CD107a (328612); anti-NKP44 (325116); anti-CD158e1 (312706); anti-CD158d (347006); anti-CD27 (356412); anti-CCR4 (359412); anti-DNAM-1 (338316); anti-CD16 (302040); anti-Granzyme B (515406); anti-CD62L (304806); anti-CD69 (310910); anti-NKP80 (346706); anti-NKP30 (325210); anti-CD158f (341304); anti-CD158b (312612); anti-Tim-3 (345012); anti-CD94 (305504); anti-TIGIT (372706); anti-TRAIL (308206); anti-CD57 (322306); anti-CX3CR1 (341610); anti-NKG2D (320808); anti-Perforin (353310); anti-Ki67 (350504); anti-IFN-γ (506518); anti-CD94 (305506); anti-NKp46 (331916); anti-CTLA4 (369614); anti-CD96 (338416); anti-41BB (309818); anti-CD25 (356108) were purchased from Biolegend. anti-CD159a/NKG2A (FAB1059P) and anti-NKG2C (FAB138G) were purchased from R&D.
The following fluorescently conjugated antibodies were used to identify immune cell types in eNK or PBMC: anti-human Lineage Cocktail (348803); anti-CD56 (362550); anti-CD3 (300430); anti-CD33 (366620); anti-HLA-DR (307606); anti-CD14 (301836); anti-CD19 (302242); anti-CD11b (301322); anti-CD25 (356108); and anti-FOXP3 (320108) were purchased from Biolegend, San Diego, CA, USA.

Chen M., Li Y., Wu Y., Xie S., Ma J., Yue J., Lv R., Tian Z., Fang F, & Xiao W. (2021). Anti-Tumor Activity of Expanded PBMC-Derived NK Cells by Feeder-Free Protocol in Ovarian Cancer. Cancers, 13(22), 5866.

+ Open protocol

+ Expand

Cytotoxicity Assay of NK Cells

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

cNK and ML NK cells were incubated with tumor targets at 5:1 ET ratio as previously described.^{13 (link),14 (link)} When indicated, cNK and ML NK cells were pre-incubated with anti-NKG2D, anti-NKp46, anti-NKp30, and anti-DNAM1 (5 µg/mL; all Biolegend) or a combination of anti-NKG2D, anti-NKp46 and anti-DNAM for 30 minutes before co-incubation with tumor targets. Cells incubated with Isotype control were used as control. At the end, the cells were stained with anti-CD56 (clone N901), anti-CD3 (clone UCHT1), anti-NKG2A (clone Z199), and anti-CD45 (clone J33) followed by intracellular staining with anti-IFN-γ (clone B27). Data was acquired in a Gallios flow cytometer (Beckman Coulter) and analyzed using FlowJo software (Tree Star v10.8).

Marin N.D., Becker-Hapak M., Song W.M., Alayo Q.A., Marsala L., Sonnek N., Berrien-Elliott M.M., Foster M., Foltz J.A., Tran J., Wong P., Cubitt C.C., Pence P., Hwang K., Zhou A.Y., Jacobs M.T., Schappe T., Russler-Germain D.A., Fields R.C., Ciorba M.A, & Fehniger T.A. (2024). Memory-like differentiation enhances NK cell responses against colorectal cancer. Oncoimmunology, 13(1), 2348254.

+ Open protocol

+ Expand

TIRF Microscopy of Myo10 and Actin

Check if the same lab product or an alternative is used in the 5 most similar protocols

For TIRF microscopy experiments (related to Fig. 3 B), cells transiently expressing bovine Myo10-mCherry were plated for 2 h on glass-bottom dishes (MatTek Corporation) precoated with 10 µg/ml bovine plasma FN overnight at 4°C.
If not stated otherwise, all samples were fixed in 4% (wt/vol) PFA for 10 min, washed with PBS, and permeabilized with PBS containing 0.5% (vol/vol) Triton X-100 for 3 min. Cells were then washed with PBS, blocked using a solution of 1 M glycine for 30 min, and incubated overnight at 4°C with Alexa Fluor 488 Phalloidin (1/100 in PBS) and, when indicated, with 1 µg/ml (in PBS) DAPI. After washing, samples were stored in PBS in the dark at 4°C before analysis. NK-92 natural killer cells were plated for 20 min on similar dishes precoated with 5 µg/ml anti-CD18 antibody (clone IB4, produced in-house) and 5 µg/ml anti-NKp30 (anti-human CD337, clone PG30.15; BioLegend).
If not stated otherwise, all live-cell imaging experiments were performed in normal growth media supplemented with 50 mM Hepes at 37°C and in the presence of 5% CO₂.

Jacquemet G., Paatero I., Carisey A.F., Padzik A., Orange J.S., Hamidi H, & Ivaska J. (2017). FiloQuant reveals increased filopodia density during breast cancer progression. The Journal of Cell Biology, 216(10), 3387-3403.

+ Open protocol

+ Expand

Blocking NK Cell Receptors Impacts Viral Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols

NK cell receptors were blocked for 30 minutes at 4°C on CYNK cells with 10 µg/ml of anti-NKp30 (clone: P30-15, Biolegend), anti-NKp44 (clone: P44-8, Biolegend), anti-NKp46 (clone: 9E2, Biolegend) and/or anti-NKG2D (clone: 1D11, Biolegend). IgG1 (clone: MOPC21, Biolegend) was used as a control. CYNK cells were then co-cultured with PR8-infected A549 cells at an E:T ratio 10:1 for 24 hours in the presence of indicated antibodies.

Gunasekaran M., Difiglia A., Fitzgerald J., Hariri R., van der Touw W, & Mahlakõiv T. (2022). Human placental hematopoietic stem cell-derived natural killer cells (CYNK) recognize and eliminate influenza A virus-infected cells. Frontiers in Immunology, 13, 900624.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!